Literature DB >> 12801589

Neurotensin agonists: possible drugs for treatment of psychostimulant abuse.

Elliott Richelson1, Mona Boules, Paul Fredrickson.   

Abstract

Although many neuropeptides have been implicated in the pathophysiology of psychostimulant abuse, the tridecapeptide neurotensin holds a prominent position in this field due to the compelling literature on this peptide and psychostimulants. These data strongly support the hypothesis that a neurotensin agonist will be clinically useful to treat the abuse of psychostimulants, including nicotine. This paper reviews the evidence for a role for neurotensin in stimulant abuse and for a neurotensin agonist for its treatment.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12801589     DOI： 10.1016/s0024-3205(03)00388-6

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  12 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

2.  Effect of low doses of methamphetamine on rat limbic-related neurotensin systems.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Synapse       Date:  2015-06-11       Impact factor: 2.562

Review 3.  Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

Authors:  Christopher L German; Michelle G Baladi; Lisa M McFadden; Glen R Hanson; Annette E Fleckenstein
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

4.  Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators.

Authors:  Anthony B Pinkerton; Satyamaheshwar Peddibhotla; Fusayo Yamamoto; Lauren M Slosky; Yushi Bai; Patrick Maloney; Paul Hershberger; Michael P Hedrick; Bekhi Falter; Robert J Ardecky; Layton H Smith; Thomas D Y Chung; Michael R Jackson; Marc G Caron; Lawrence S Barak
Journal:  J Med Chem       Date:  2019-08-20       Impact factor: 7.446

5.  Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference.

Authors:  Klara Felszeghy; José Manuel Espinosa; Hélène Scarna; Anne Bérod; William Rostène; Didier Pélaprat
Journal:  Neuropsychopharmacology       Date:  2007-03-14       Impact factor: 7.853

6.  Responses of the rat basal ganglia neurotensin systems to low doses of methamphetamine.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

7.  The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex.

Authors:  Zhimin Li; Mona Boules; Katrina Williams; Joanna Peris; Elliott Richelson
Journal:  Brain Res       Date:  2009-11-27       Impact factor: 3.252

Review 8.  The drive to eat: comparisons and distinctions between mechanisms of food reward and drug addiction.

Authors:  Ralph J DiLeone; Jane R Taylor; Marina R Picciotto
Journal:  Nat Neurosci       Date:  2012-09-25       Impact factor: 24.884

9.  ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse.

Authors:  Larry S Barak; Yushi Bai; Sean Peterson; Tama Evron; Nikhil M Urs; Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick R Maloney; Thomas D Y Chung; Ramona M Rodriguiz; William C Wetsel; James B Thomas; Glen R Hanson; Anthony B Pinkerton; Marc G Caron
Journal:  ACS Chem Biol       Date:  2016-05-05       Impact factor: 5.100

10.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.